Semarion Secures $3.8M to Advance Drug Discovery Tech
CAMBRIDGE, UK, March 31, 2026 Semarion, a University of Cambridge spin-out company, has announced the successful raise of $3.8...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CAMBRIDGE, UK, March 31, 2026 Semarion, a University of Cambridge spin-out company, has announced the successful raise of $3.8...
New York, NY — December 2, 2025 — A newly released industry analysis reveals that the Life Science Automation...
Lexington, Massachusetts – October 30, 2025 — Rapid Micro Biosystems, Inc. (Nasdaq: RPID), a leader in automated microbial quality...
